NOBLADS Score Calculator — Severe Lower GI Bleeding Prediction

Clinical Parameters at Presentation

Check all criteria present at time of assessment:

NSAIDs Use Current or recent non-steroidal anti-inflammatory drug use

No Oral Anticoagulant Patient is NOT on oral anticoagulants (score 1 if anticoagulant-free)

Blood Pressure < 100 mmHg Systolic BP below 100 mmHg on arrival

≥2 Comorbidities CVD, DM, hepatic disease, renal disease, pulmonary disease, or malignancy

Albumin < 30 g/L (< 3.0 g/dL) Low serum albumin at presentation

Diverticular Disease Known or suspected diverticular disease as underlying cause

Syncope on Admission Loss of consciousness or near-syncope related to bleeding

—

Check criteria above

NOBLADS Acronym

Letter	Full Name	Criterion	Points
N	NSAIDs	Current / recent NSAID use	1
O	No Oral Anticoagulant	Patient NOT on oral anticoagulants	1
B	Blood Pressure	Systolic BP <100 mmHg on arrival	1
L	Load of comorbidities	≥2 comorbidities (CVD / DM / hepatic / renal / pulmonary / malignancy)	1
A	Albumin	<30 g/L (<3.0 g/dL)	1
D	Diverticular disease	As likely aetiology	1
S	Syncope	On admission	1

Total score: 0–7. Each criterion present scores 1 point.

Interpretation

Score	Risk	Probability of Severe Bleeding	Action
0–2	Lower Probability	Lower risk	Standard monitoring. Elective colonoscopy within 48–72 hours after bowel preparation.
3–4	High Probability	~60%	Admit to HDU. Early colonoscopy within 24 hours. Anticipate transfusion. IV access and group & crossmatch.
5–7	Very High Probability	>80%	ICU-level care. Urgent colonoscopy or CT angiography. Haemostatic interventions likely required. Surgical backup on standby.

Definition of Severe LGIB

The NOBLADS score was designed to predict the composite outcome of severe lower GI bleeding, defined as any of the following:

Transfusion requirement of ≥4 units of packed red blood cells within 24 hours of presentation.
Need for endoscopic haemostasis, transcatheter arterial embolisation (TAE), or surgical intervention.
Rebleeding within 30 days requiring re-intervention.

Explanation of the "O" Variable — No Oral Anticoagulant

The "O" criterion is counterintuitive: patients who are not on oral anticoagulants score 1 point, seemingly increasing their risk score. The rationale lies in bleeding source epidemiology:

In the original derivation cohort, the majority of severe lower GI bleeds arose from diverticular disease and vascular ectasia — conditions characterised by arterial-type bleeding that tends to be brisk and severe regardless of anticoagulant status.
Patients on anticoagulants (warfarin, DOACs) more commonly bleed from mucosal sources such as haemorrhoids, colitis, or erosions — bleeds that are often self-limited and respond to correction of anticoagulation.
This variable therefore reflects the pattern of bleeding aetiology in the study population, not a direct protective effect of anticoagulation itself.
Clinically, anticoagulation still requires assessment and reversal where appropriate — the score does not imply that anticoagulated patients are safe to ignore.

Comparison with Oakland Score

The Oakland Score and NOBLADS Score are complementary tools that address different clinical decisions in acute LGIB:

Oakland Score: predicts safe discharge — primary outcome is absence of rebleeding, transfusion, or death within 28 days. Answers: can this patient go home safely?
NOBLADS Score: predicts severity — likelihood of requiring ≥4 units of blood, endoscopic or angiographic intervention, or rebleeding. Answers: how severe will this bleed become?
Recommended workflow: use Oakland to triage between discharge and admission; use NOBLADS for admitted patients to allocate HDU vs. ICU care and plan blood product and procedural resources.
Important caveat: NOBLADS was derived and validated primarily in a Japanese tertiary centre. External validation in Western populations is limited, and performance may differ in settings with different LGIB aetiology distributions.

Limitations

Japanese derivation: the score was derived and validated primarily at a single Japanese tertiary centre (Aoki 2015). Western external validation is limited; the score may under-represent IBD-related LGIB, which is more prevalent in Western populations.
Comorbidity count ("L" variable): requires systematically counting six specific comorbidity categories, which may introduce subjective variability in clinical practice.
Binary scoring: each criterion is scored 0 or 1, with no weighting for severity — a patient with a systolic BP of 99 mmHg scores the same as one with a BP of 60 mmHg.
Albumin availability: serum albumin may not be immediately available at first assessment in all emergency settings, potentially delaying calculation.

References

Aoki T, et al. Development and validation of a risk scoring system for severe acute lower gastrointestinal bleeding. Dig Dis Sci. 2015;60(6):1843–1851.

NOBLADS Score